Ankit Mahadevia - Feb 1, 2023 Form 4 Insider Report for Spero Therapeutics, Inc. (SPRO)

Role
CEO and President, Director
Signature
/s/ Tamara Joseph, Attorney-in-Fact for Ankit Mahadevia
Stock symbol
SPRO
Transactions as of
Feb 1, 2023
Transactions value $
$0
Form type
4
Date filed
2/3/2023, 06:38 PM
Previous filing
Feb 3, 2022
Next filing
Feb 6, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SPRO Common Stock Award $0 +532K +191.2% $0.00 810K Feb 1, 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in four equal annual installments beginning on February 1, 2024, subject to the Reporting Person's continued service through the applicable vesting date.
F2 Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee. Amount also includes 691,205 RSUs held by the Reporting Person.